Adverse interactions of rofecoxib with lisinopril in spontaneously hypertensive rats

Clinical Toxicology

Volumn 43, Issue 5, 2005, Pages 361-373

  Dubey, Kiran ^a   Balani, Dayal K ^b   Tripathi, C B ^c   Singh, Rajvir ^d   Bajaj, Rajiv ^e   Pillai, K K ^a  

^a HAMDARD UNIVERSITY   (India)

^b CCS HARYANA AGRICULTURAL UNIVERSITY   (India)

^c INSTITUTE OF HUMAN BEHAVIOUR AND ALLIED SCIENCES   (India)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^e Batra Hospital India   (India)

Author keywords

Adverse interaction; Antihypertensive; Rofecoxib; Spontaneously hypertensive rats

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDOMETACIN; LISINOPRIL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTHRITIS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; HEART PROTECTION; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; NONHUMAN; PROTON SODIUM EXCHANGE; RAT; RENAL PROTECTION; SPONTANEOUSLY HYPERTENSIVE RAT;

AGE FACTORS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; CELL NUCLEUS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ERYTHROCYTES; HEART RATE; KIDNEY; LACTONES; LISINOPRIL; MEN; MYOCYTES, CARDIAC; RATS; RATS, INBRED SHR; RATS, WISTAR; SODIUM; SODIUM-HYDROGEN ANTIPORTER; SULFONES; TOXICITY TESTS;

ANIMALIA; RATTUS NORVEGICUS;

EID: 26444469949     PISSN: 07313810     EISSN: 10979875     Source Type: Journal    
DOI: 10.1081/CLT-200066053     Document Type: Article

References (63)

1. Penglis PS, James MJ, Cleland LG. Cyclooxygenase inhibitors: any reservations? IMJ 2001; 31(1):37-41.
2. Fujita T, Yamashita N, Yamashita K. Effect of indomethacin on antihypertensive action of captopril in hypertensive patients. Clin Exp Hypertens 1981; 3:939-952.
3. Silverbauer K, Stanek B, Tempel H. Acute hypotensive effect of captopril modified by prostaglandin synthesis inhibition. Br J Clin Pharmacol 1982; 14:87S-93S.
4. FitzGerald GA, Cheng Y, Austin S. COX-2 inhibitors and the cardiovascular system. Clin Exp Rheumatol 2001; 19(suppl 25):S31-S36.
5. Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arellano FM. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre Safety database. Clin Ther 2001; 23(9):1478-1491.
6. Cleland LG, James MJ, Stamp LK, Penglis PS. COX-2 inhibition and thrombotic tendency: a need for surveillance. Med J Aust 2001; 175:214-217.
7. Dubey K, Balani DK, Pillai KK. Potential adverse interaction between aspirin and lisinopril in hypertensive rats. Human Exp Toxicol 2003; 22:143-147.
8. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality and morbidity after acute myocardial infarction: subgroup analysis of the Co-operative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79:115-119.
9. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821-828.
10. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial. J Am Coll Cardiol 1998; 31:419-425.
11. Leor J, Reicher-Reiss H, Goldbourt U, Boyko V, Gottlieb S, Battler A, Behar S. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. A cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999; 33:1920-1925.
12. Latini R, Tognoni G, Maggioni AP, Baigent C, Braunwald E, Chen Z, Collins R, Rather M, Franzosi M, Kjekshus J, Kober L, Liu L, Peto R, Pfeffer M, Pizzetti F, Santoro E, Sleight P, Swedberg K, Tavazzi L, Wang W, Yusuf S, On Behalf of the Angiotensin-Converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. Systematic overview of individual data from 96,712 randomized patients. J Am Coll Cardiol 2000; 35:1801-1807.
13. Fourth International Study of Infarct Survival (ISIS-4) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345:669-685.
14. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963; 27:282-293.
15. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 1998; 39:89-105.
16. Rosskopf D, Düsing R, Siffert W. Membrane sodium-proton exchange and primary hypertension. Hypertension 1993; 21:607-617.
17. Feig PU, D'Occhio MA, Boylan JW. Lymphocyte membrane sodium-proton exchange in spontaneously hypertensive rats. Hypertension 1987; 9:282-288.
18. + exchange. J Clin Invest 1989; 83:822-829.
19. + exchanger expression in vascular smooth muscle of spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 1994; 24:734-738.
20. + exchange and other ion-transport systems in erythrocytes of essential hypertensives and spontaneously hypertensive rats: a comparative analysis. J Hypertens 1989; 7:781-788.
21. + exchange activity in normotensive and hypertensive subjects: effect of enalapril therapy upon antiport activity. J Hypertens 1992; 10:839-847.
22. + exchanger overactivity in essential hypertension. Am J Hypertens 1997; 10:84-93.
23. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83(5):1771-1779.
24. Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar BM. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol 2001; 132(7):1565-1573.
25. Laudanno OM, Cesolari JA, Esnarriaga J, Rista L, Piombo G, Maglione C, Aramberry L, Sambrano J, Godoy A, Rocaspana A. Gastrointestinal damage induced by celecoxib and rofecoxib in rats. Dig Dis Sci 2001; 46(4):779-784.
26. deBlois D, Tea BS, Dam TV, Tremblay J, Hamet P. Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension 1997; 29(2):340-349.
27. Black MJ, Kanellakis P, Bobik A. Role of angiotensin II in early cardiovascular growth and vascular amplifier development in spontaneously hypertensive rats. J Hypertens 1997; 15:945-954.
28. + exchange inhibitors in cardiac ischemia. J Mol Cell Cardiol 1992; 24:731-740.
29. + exchange inhibitor and its effects in cardiac ischemia. Br J Pharmacol 1993; 109:562-568.
30. Jackson LM, Hawkey CJ. COX-2 selective non steroidal anti-inflammatory drugs. Do they really offer any advantages? Drugs 2000; 59(6):1207-1216.
31. Hochberg MC. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Clin Exp Rheumatol 2001; 19(suppl 25):S15-S22.
32. Abramson SB, Furst DE, Hochberg MC, Patrono C. Controversies in COX-2 inhibitor therapy: closing remarks. Clin Exp Rheumatol 2001; 19(suppl 25):S77-S80.
33. Verma S, Szmitko PE. Coxibs and the endothelium. J Am Coll Cardiol 2003; 42(10):1754-1756.
34. Cleland JGF. No reduction in cardiovascular risk with NSAIDs-including aspirin? Lancet 2002; 359:92-93.
35. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvein TK, Schnitzer TJ, The Vigor Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-1528.
36. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs. non steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284:1247-1255.
37. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286(8):954-959.
38. Wallace JL, Bak A, Mcknight W, Asfaha S, Sharkey KA, MacNaughton WK. Cyclooxygenase-1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 1998; 115:101-109.
39. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289(2):735-741.
40. Whelton A, Brater DC, Sica DA. Effects of celecoxib and naproxen on renal function in the elderly. J Am Soc Nephrol 1999; 10:92A.
41. Höcherl K, Endemann D, Kammerl MC, Grobecker HF, Kurtz A. Cyclooxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol 2002; 136:1117-1126.
42. Whelton A, White WB, Bello AE, Puma JA, Fort JG, SUCCESS VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90(9):959-963.
43. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM, SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardio renal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8(2):85-95.
44. Sandler DP, Burr R, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115(3):165-172.
45. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991; 31:588-598.
46. Kendell MJ, Horton RC. Clinical pharmacology and therapeutics. Postgrad Med J 1990; 66:166-185.
47. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94:2504-2510.
48. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol, Renal 2001; 281:F1-F11.
49. Lorenz JN, Greenberg SG, Briggs JP. The macula densa mechanism for control of renin secretion. Semin Nephrol 1993; 13(6):531-542.
50. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315:983-989.
51. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A. Cyclooxygenase-2 mediates the cardioprotective effects of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A 2000; 97:10197-10202.
52. Naproxen: Long term study indicates cardiovascular risk. WHO Pharmaceuticals Newsletter, prepared in collaboration with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden, 2005; 1:4.
53. FDA Alert for Practitioners (Celecoxib), 17 December 2004, Available at http://www.fda.gov.
54. Hall D. The aspirin-angiotensin converting enzyme inhibitor trade off: to halve and halve not. J Am Coll Cardiol 2000; 35:1808-1812.
55. Adams MA, Bobik A, Komer PI. Differential development of vascular and cardiac hypertrophy in genetic hypertension. Hypertension 1989; 14:191-201.
56. McGuire PG, Tweitmeyer TA. Aortic endothelial functions in developing hypertension. Hypertension 1985; 7:483-490.
57. + cellular metabolism. Clin Sci 1981; 61:181-186.
58. Hilton P. Cellular sodium transport in essential hypertension. N Engl J Med 1986; 314:222-229.
59. Parker JC, Berkowitz LR. Physiologically instructive genetic variants involving in human red cell. Physiol Rev 1983; 63:261-313.
60. Simon G. Is intracellular sodium increased in hypertension? Clin Sci 1989; 76:455-461.
61. Siffert W, Düsing R. Sodium-proton exchange and primary hypertension. An update. Hypertension 1995; 26:649-655.
62. Canessa M, Morgan K, Goldszer R, Moore TJ, Spalvins A. Kinetic abnormalities of the red blood cell sodium-proton exchange in hypertensive patients. Hypertension 1991; 17:340-348.
63. + exchanger: a potential therapeutic target for the prevention of myocardial ischaemic and reperfusion injury and attenuation of postinfarction heart failure. Drugs 2001; 61(3):375-389.